Efficacy of Intravenously Administered Gepotidacin in Cynomolgus Macaques following a Francisella tularensis Inhalational Challenge
Open Access
- 17 May 2023
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (5) , e0138122
Abstract
Francisella tularensis ( F. tularensis ) is a Centers for Disease Control (CDC) category “A” Gram-negative biothreat pathogen. Inhalation of F. tularensis can cause pneumonia and respiratory failure and is associated with high mortality rates without early treatment.Keywords
Funding Information
- US | Defense Threat Reduction Agency (Agreement number HDTRA1-07-9-00021)
- GlaxoSmithKline
This publication has 32 references indexed in Scilit:
- Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection ModelAntimicrobial Agents and Chemotherapy, 2015
- Comparison of experimental respiratory tularemia in three nonhuman primate speciesComparative Immunology, Microbiology and Infectious Diseases, 2015
- The atypical lipopolysaccharide ofFrancisellaCarbohydrate Research, 2013
- Mechanisms of Francisella tularensis Intracellular PathogenesisCold Spring Harbor Perspectives in Medicine, 2013
- Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistanceNature Structural & Molecular Biology, 2010
- Bioterrorism: From Threat to RealityAnnual Review of Microbiology, 2002
- TularemiaClinical Microbiology Reviews, 2002
- Tularemia as a Biological WeaponJAMA, 2001
- Comparative deposition of inhaled aerosols in experimental animals and humans: A reviewJournal of Toxicology and Environmental Health, 1985
- Tularemia Vaccine StudyArchives of internal medicine (1960), 1961